The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3
Abstract
Development of drug resistance is one of the major obstacles in cancer chemotherapy. The molecular mechanism leading to drug resistance is still not fully understood. A10A cells, a doxorubicin-resistant subline of human squamous cell carcinoma A431 cells, showed cross-resistance to methotrexate and also resistance to the drug-induced apoptosis. The cells also showed overexpression of a mutated form of p53, p53-R273H (Arg to His at codon 273), and down-regulation of procaspase-3. Knockdown of p53-R273H by p53 small interfering RNA in A431 cells increased procaspase-3 level and sensitized the cells to drug-induced apoptosis. On the other hand, transfection of p53-R273H into p53 null human osteosarcoma Saos-2 cells down-regulated procaspase-3 level and induced resistance to the drug toxicity and drug-induced apoptosis. The results support the idea that p53-R273H may gain new functions in induction of drug resistance and impairment in drug-induced apoptosis through down-regulation of procaspase-3 level. The study sheds new light on the understanding of the gain of function and drug resistance mechanisms associated with mutant p53. [Mol Cancer Ther 2007;6(3):1054–8]
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In R273H-expressing human squamous cell carcinoma cells, multidrug resistance to doxorubicin, methotrexate and apoptosis-inducing drugs was shown due to downregulation of procaspase-3 levels.257”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [257]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418
Mutant p53 Cooperates with ETS and Selectively Up-regulates Human MDR1 Not MRP1
Sampath, J., Sun, D., Kidd, V. J., Grenet, J., Gandhi, A., Shapiro, L. H., Wang, Q., Zambetti, G. P., & Schuetz, J. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103429200 · Cited by 244
Zalcenstein, A., Stambolsky, P., Weisz, L., Müller, M., Wallach, D., Goncharov, T. M., Krammer, P. H., Rotter, V., & Oren, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206724 · Cited by 123
Research works printed but not linked: 30
- Hollstein M, Moeckel G, Hergenhahn M, et al. On the origins of tumor mutations in cancer genes: insights from the p53 gene. Mutat Res 1998;405:145–54. · DOI
- Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000;77:81–137. · DOI · Paper page
- Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323–31. · DOI · Paper page
- Prives C, Hall PA. The p53 pathway. J Pathol 1999;187:112–26. · doi:10.1002/(sici)1096-9896(199901)187:1<112::aid-path250>3.0.co;2-3
- Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000;60:6788–93.
- Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in p53. Nat Genet 1993;4:42–6. · DOI · Paper page
- van Oijen MG, Slootweg PJ. Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 2000;6:2138–45.
- Kim E, Deppert W. Transcriptional activities of mutant p53: when mutations are more than a loss. J Cell Biochem 2004;93:878–86. · DOI
- Linn SC, Honkoop AH, Hoekman K, van der Valk P, Pinedo HM, Giaccone G. p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer 1996;74:63–8. · DOI
- Vasey PA, Jones NA, Jenkins S, Dive C, Brown R. Cisplatin, camptothecin, and Taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 1996;50:1536–40.
- Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999;18:477–85. · DOI · Paper page
- Pugacheva EN, Ivanov AV, Kravchenko JE, Kopnin BP, Levine AJ, Chumakov PM. Novel gain of function activity of p53 mutants: activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene 2002;21:4595–600. · DOI
- Tsang WP, Ho FY, Fung KP, Kong SK, Kwok TT. p53-175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer 2005;114:331–6. · DOI
- Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene 2006;25:304–9. · DOI · Paper page
- Kwok TT, Sutherland RM. Epidermal growth factor reduces resistance to doxorubicin. Int J Cancer 1991;49:73–6. · doi:10.1002/ijc.2910490114
- Twomey C, McCarthy JV. Pathways of apoptosis and importance in development. J Cell Mol Med 2005;9:345–59. · DOI
- Wang ZB, Liu YQ, Cui YF. Pathways to caspase activation. Cell Biol Int 2005;29:489–96. · DOI · Paper page
- Kwok TT, Mok CH, Menton-Brennan L. Up-regulation of a mutant form of p53 by doxorubicin in human squamous carcinoma cells. Cancer Res 1994;54:2834–6.
- Ceruti S, Beltrami E, Matarrese P, et al. A key role for caspase-2 and caspase-3 in the apoptosis induced by 2-chloro-2′-deoxy-adenosine (cladribine) and 2-chloro-adenosine in human astrocytoma cells. Mol Pharmacol 2003;63:1437–47. · doi:10.1124/mol.63.6.1437
- Hishita T, Tada-Oikawa S, Tohyama K, et al. Caspase-3 activation by lysosomal enzymes in cytochrome c-independent apoptosis in myelodysplastic syndrome-derived cell line P39. Cancer Res 2001;61:2878–84.
- Yang L, Cao Z, Yan H, Wood WC. Coexistence of high levels of apoptotic signaling and inhibitors of apoptosis proteins in human tumor cells: Implication for cancer specific therapy. Cancer Res 2003;63:6815–24.
- Mashima T, Oh-hara T, Sato S, et al. p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target. J Natl Cancer Inst 2005;97:765–77. · DOI
- Schafer ZT, Parrish AB, Wright KM, et al. Enhanced sensitivity to cytochrome c-induced apoptosis mediated by PHAPI in breast cancer cells. Cancer Res 2006;66:2210–8. · DOI
- O'Farrell TJ, Ghosh P, Dobashi N, Sasaki CY, Longo DL. Comparison of the effect of mutant and wild-type p53 on global gene expression. Cancer Res 2004;64:8199–207. · DOI · Paper page
- Weisz L, Zalcenstein A, Stambolsky P, et al. Transactivation of the EGR1 gene contributes to mutant p53 gain of function. Cancer Res 2004;64:8318–27. · DOI
- Teitz T, Wei T, Valentine MB, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000;6:529–35. · DOI · Paper page
- Liu W, Wang G, Yakovlev AG. Identification and functional analysis of the rat caspase-3 gene promoter. J Biol Chem 2002;277:8273–8. · DOI
- Liedtke C, Groger N, Manns MP, Trautwein C. The human caspase-8 promoter sustains basal activity through SP1 and ETS-like transcription factors and can be up-regulated by a p53-dependent mechanism. J Biol Chem 2003;278:27593–604. · DOI
- Tsujimoto K, Ono T, Sato M, Nishida T, Oguma T, Tadakuma T. Regulation of the expression of caspase-9 by the transcription factor activator protein-4 in glucocorticoid-induced apoptosis. J Biol Chem 2005;280:27638–44. · DOI
- Sabbagh L, Bourbonniere M, Denis F, Sekaly RP. Cloning and functional characterization of the murine caspase-3 gene promoter. DNA Cell Biol 2006;25:104–15. · DOI
Cited by
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Mutant p53 Gain-of-Function in Cancer
Oren, M., & Rotter, V. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001107 · Cited by 753
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101205 · Cited by 294
Metadata
- Authors
- Wong, R. P. C., Tsang, W. P., Chau, P. Y., Co, N. N., Tsang, T. Y., & Kwok, T. T.
- Affiliations
- Department of Biochemistry, The Chinese University of Hong Kong, Hong Kong SAR, China
- Venue
- Molecular Cancer Therapeutics
- Published
- 2007-03-01
- Volume
- 6
- Issue
- 3
- Pages
- 1054-1061
- ISSN
- 1535-7163
- 1538-8514
- Cited by
- 87
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. https://app.cochat.ai/papers/10.1158/1535-7163.mct-06-0336
- The paper
- Wong, R. P. C., Tsang, W. P., Chau, P. Y., Co, N. N., Tsang, T. Y., & Kwok, T. T. (2007). p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-06-0336
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.